Forever Labs to Utilize Data Collection Platform DataBiologics
Ann Arbor, Michigan, September 9, 2021 — Forever Labs, the parent company of SuperShot® PRP, will utilize DataBiologics to track outcomes for their patented PRP process that allows autologous extracellular vesicles to be isolated. Physicians who already collect, review and analyze data related to their orthobiologic treatment outcomes via the DataBiologics platform can now include SuperShot® PRP procedures in their data. This newly collected data can then be compared to outcomes for standard PRP procedures. By using DataBiologics, Forever Labs is ensuring that the safety and efficacy of SuperShot® PRP is tracked and monitored, a top priority for the Forever Labs team. “We developed SuperShot PRP to give clinicians the ability to add autologous extracellular vesicles to their PRP therapies. ...